Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells

Authors

+9 authors

Journal

Published

Mar 5, 2014

DOI

Save

Tip

Document

Download

Flag content

Tip

Save

Document

Download

Flag content

Abstract

Key Points Targeting of CD123 via CAR-engineered T cells results in rejection of human AML and myeloablation in mouse models.

This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.